Articles with public access mandates - Maria Carmela PiccirilloLearn more
Not available anywhere: 7
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
S Pignata, G Scambia, D Katsaros, C Gallo, E Pujade-Lauraine, ...
The Lancet Oncology 15 (4), 396-405, 2014
Mandates: US National Institutes of Health
Treatment of small cell lung cancer
A Morabito, G Carillio, G Daniele, MC Piccirillo, A Montanino, R Costanzo, ...
Critical reviews in oncology/hematology 91 (3), 257-270, 2014
Mandates: US National Institutes of Health
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized …
C Gridelli, A Morabito, V Gebbia, M Mencoboni, F Carrozza, MG Viganò, ...
Lung Cancer 67 (1), 86-92, 2010
Mandates: US National Institutes of Health
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
G Daniele, F Raspagliesi, G Scambia, C Pisano, N Colombo, S Frezzini, ...
International Journal of Gynecologic Cancer 31 (6), 2021
Mandates: US National Institutes of Health, AIRC Foundation for Cancer Research in Italy
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis …
A Morabito, MC Piccirillo, P Maione, A Luciani, L Cavanna, L Bonanno, ...
Lung Cancer 133, 62-68, 2019
Mandates: Government of Italy
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial
R Di Liello, L Arenare, F Raspagliesi, G Scambia, C Pisano, N Colombo, ...
International Journal of Gynecologic Cancer 31 (10), 2021
Mandates: US National Institutes of Health, AIRC Foundation for Cancer Research in Italy
Endocrine Effects of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Breast Cancer Patients.
MC Piccirillo, G Esposito, MD Maio, G Daniele, P Giordano, FD Rella, ...
European Journal of Clinical & Medical Oncology 3 (1), 2011
Mandates: US National Institutes of Health
Available somewhere: 32
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non–small-cell lung cancer: the TORCH randomized trial
C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts, V Gebbia, P Maione, ...
Journal of Clinical Oncology 30 (24), 3002-3011, 2012
Mandates: US National Institutes of Health
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian …
U Wagner, C Marth, R Largillier, J Kaern, C Brown, M Heywood, ...
British journal of cancer 107 (4), 588-591, 2012
Mandates: US National Institutes of Health
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase …
S Pignata, D Lorusso, G Scambia, D Sambataro, S Tamberi, S Cinieri, ...
The Lancet Oncology 16 (5), 561-568, 2015
Mandates: US National Institutes of Health
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy
F Perrone, C Jommi, M Di Maio, A Gimigliano, C Gridelli, S Pignata, ...
Annals of oncology 27 (12), 2224-2229, 2016
Mandates: US National Institutes of Health
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ...
The Lancet Oncology 19 (4), 474-485, 2018
Mandates: Government of Italy
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2. 16, ENGOT-Ov1, GCIG …
S Pignata, G Scambia, A Bologna, S Signoriello, IB Vergote, U Wagner, ...
Journal of Clinical Oncology 35 (29), 3347-3353, 2017
Mandates: Federal Ministry of Education and Research, Germany
Cisplatin-based first-line treatment of elderly patients with advanced non–small-cell lung cancer: joint analysis of MILES-3 and MILES-4 phase III trials
C Gridelli, A Morabito, L Cavanna, A Luciani, P Maione, L Bonanno, ...
Journal of Clinical Oncology 36 (25), 2585-2592, 2018
Mandates: US National Institutes of Health, Government of Italy
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study
A Morabito, V Gebbia, M Di Maio, S Cinieri, MG Viganò, R Bianco, ...
Lung cancer 81 (1), 77-83, 2013
Mandates: US National Institutes of Health
Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score
British journal of surgery 108 (11), 1274-1292, 2021
Mandates: US National Institutes of Health, British Heart Foundation, National …
Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors
P Giordano, A Manzo, A Montanino, R Costanzo, C Sandomenico, ...
Critical reviews in oncology/hematology 97, 143-151, 2016
Mandates: US National Institutes of Health
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid-short …
A Avallone, MC Piccirillo, P Delrio, B Pecori, E Di Gennaro, L Aloj, ...
BMC cancer 14, 1-12, 2014
Mandates: Government of Italy
The time to offer treatments for COVID-19
BT Ngo, P Marik, P Kory, L Shapiro, R Thomadsen, J Iglesias, S Ditmore, ...
Expert opinion on investigational drugs 30 (5), 505-518, 2021
Mandates: US Department of Veterans Affairs
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): a subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial
G Daniele, D Lorusso, G Scambia, SC Cecere, MO Nicoletto, E Breda, ...
Gynecologic Oncology 144 (2), 256-259, 2017
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program